NEWS

March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women

Orexa

Orexa is S1 Biopharma’s first therapy for erectile dysfunction (ED).

S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com